In this new era of targeted therapies, the role of clinical trials is more important than ever in providing patients with access to promising new therapies and advancing our knowledge through cutting-edge research.
Compass Oncology also participates in clinical trials through Sarah Cannon Research Institute (SCRI), a joint venture with US Oncology Research and one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 600 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today.
At Compass Oncology, we sponsor more clinical trials than any other cancer treatment facility in the Portland-Vancouver area. Continuing to provide our community with access to promising new therapies that may become tomorrow's gold standard remains a top priority at Compass Oncology.